TransCelerate BioPharma, Inc. Clinical Data Standards Project. Dave Jordan Data Standards Project Leader

Similar documents
CDISC/TransCelerate Collaboration and TransCelerate work streams. -Clinical Data Standards -Common Protocol Template -esource

Pre-Competitive Collaboration in Clinical Trials. July 24, 2013 Garry A. Neil, MD Board of Directors, Chairman

CDISC and Clinical Research Standards in the LHS

CDISC Journal. Current status and future scope of CDISC standards. By Rebecca D. Kush, President and CEO, CDISC. 1. Introduction

CDASH Clinical Data Acquisition Standards Harmonization

End-to-End Management of Clinical Trials Data

CDISC Standards: Current and Future

October, Integration and Implementation of CDISC Standards

CDISC UK Network face to face Reading

Evolving Regulatory Guidance on Submission of Standardized Data. James R. Johnson, PhD RTP CDISC User Network

Industrialized Clinical Data Standards Management Speed of automation, Power of accuracy and Transforming clinical data into business intelligence

CFAST Therapeutic Area Program Steering Committee 2013 Meeting Summaries (January-August)

CDISC Controlled Terminology across the Clinical Trial Continuum. Bay Area Implementation Network 6 March 2008

CDISC Data Standards Validation

Clinical Data Standards Governance. Tammy Burns, Expert Clinical Data Manager 11 th January 2013

CDISC Production Standards Status & Plans

Statistical Review and Data Standards: It s Gettin Better All The Time

The use of electronic Health Records in Clinical Research - The value of CDISC Standards

PharmaSUG Paper PO12

CDASH 2.0. Berlin Éanna Kiely CDISC Engineer

Roadmap for Managing Multiple CRO Vendors

From Standards that Cost to Standards that Save: Cost Effective Standards Implementation

Putting CDISC Standards to Work How Converting to CDISC Standards Early in the Clinical Trial Process Will Make Your CDISC Investment Pay

CDISC Tech Webinar Leveraging CDISC Standards to Drive Crosstrial Analytics; Graph Technology and A3 Informatics 26 OCT 2017

Critical Path Initiative: An Update

Steps and Slides of Implementing Global Standards Producing High Quality Programming Outputs Edition

CSR STRATEGY, GOVERNANCE & MATERIALITY

CRO partner in Rx/CDx Co-Development

CDISC International Interchange Program Embracing a Changing Landscape Standards to Connect Research and Patient Care

Implementation and Operation of CDISC ODM-based EDC by UMIN

Biomarker Data Management in Clinical Trials: Addressing the Challenges of the New Regulatory Landscape

HD Regulatory Science Consortium (HD-RSC) A consortium aimed at accelerating treatments for Huntington s disease

The In Vitro Diagnostic CRO

Clinical Data Acquisition Standards Harmonization (CDASH)

Welcome to the American College of Toxicology s Webinar Series. We will begin at 11AM EDT

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS

ISO INTERNATIONAL STANDARD. Health informatics Requirements for an electronic health record architecture

Visualising CDISC SDTM for Monitoring and Review. Philip C. M. Bartle Clinical Innovation, PPD

Model-Based Qualification of Biomarkers. Klaus Romero, MD MS FCP Director of Clinical Pharmacology and Quantitative Medicine

PharmaSUG 2017 Paper DS14

Janus Clinical Trials Repository: Modernizing the Review Process through Innovation

LOINC in Regulated Clinical Research a Lab LOINC Steeringg Committee Meeting 08 June 2017

Electronic Health Records and Clinical Data Interchange Standards

The Anatomy of Clinical Trials Data: A Beginner s Guide

Chapter 1. Pharmaceutical Industry Overview

An integrated model approach to improve the management of marketed products

Big Data & Clinical Informatics

THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION

Klaus Romero MD MS FCP. (Supported by the CAMD AD Modeling & Simulation Team)

Making Life Easier for Investigators: A Shared Solution for Smarter, Faster Clinical Trials

The SDTMIG: What s New in 3.2

Question and Answer Guide Regarding Notification on Practical Operations of Electronic Study Data Submissions

The Role of the CRO in Effective Risk-Based Monitoring

Deployment of SAS Programming Contract Staff: Pathway to Sinkhole or Best Strategy for Programming Division? Parag Shiralkar, Eliassen Group, NJ, USA

Eileen Navarro MD, FACP Medical Officer, OCS, OTS, CDER, FDA

June 7, Harold E. Varmus, MD Director National Cancer Institute 31 Center Drive Building 31 Room 11A48 MSC 2590 Bethesda, Maryland

Leveraging of CDISC Standards to Support Dissemination, Integration and Analysis of Raw Clinical Trials Data to Advance Open Science

Making Cloud R&D Electronic Laboratory Environments a Reality

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

Good Clinical Practice (GCP) & Clinical Trial Registries

ZS Medical Affairs Outlook Report Analysis of Field Medical Growth and Industry Trends

Pharmamarketing - strategic challenges

Oracle Buys ClearTrial Adds Leading Cloud-based Clinical Trial Operations and Analytics Applications to the Oracle Health Sciences Suite

Exploration des données d essais cliniques en utilisant le standard CDISC

Aepodia is a team of experts with more than 15 years

Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y

International Transfers of Personal Data at sanofi-aventis R & D

Rare Diseases: Challenges and Opportunities NIH Perspective

The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016

EHR4CR DEPLOYING INNOVATIVE CLINICAL TRIAL SERVICES. Brecht Claerhout, Custodix NV on behalf of the EHR4CR Consortium

The Promise and Challenge of Adaptive Design in Oncology Trials

Management in Pharmaceutical Industry

EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY

Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts

BUSINESS INTELLIGENCE & ANALYTICS

Establishment of Clinical Trial Infrastructure

Specific pathologist responses for Standard for Exchange of Nonclinical Data (SEND)

Do We Need Medical Affairs?

esource Advancement Roundtable

PAREXEL STRATEGIC PARTNERSHIPS. Optimizing relationships for shorter time to market

Executive Compensation

Devices, Big Data, and Real World Evidence O R A C L E W H I T E P A P E R O C T O B E R

Global Clinical Trials in Korea

Complex Generics: Charting a new path

Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015

Pharma Medical Affairs 2020 and beyond. Matthias Evers Edd Fleming Arnab Ghatak Jan Hartmann Arif Nathoo Ron Piervincenzi Lawrence Wai Ann Westra

EAUTIFUL BDATA AGGREGATION EXTRAVAGANZA. Implementing a Clinical Data Repository and Analytics Platform in 90 Days

Business Architecture Fundamentals

Q10 PHARMACEUTICAL QUALITY SYSTEM

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

EU perspective: European procedure for Qualification of novel methodologies for medicine development. Elmer Schabel MD

Innovative strategies to improve R&D ROI

Optimizing Your Study Data Submissions to FDA Updates from CDER and CBER

MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155

How to Reward Innovation and Value in Comparative Effectiveness Research

Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013

NCI Research Networks Model for Collaboration with Bioelectronics Round Table

Saudi FDA Drug Approval Process. Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority

Welcome to the 10 th Annual Meeting of ISMPP! Leading Through Collaboration

Venture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program. A FasterCures Webinar June 19, 2013

Transcription:

TransCelerate BioPharma, Inc. Clinical Data Standards Project Dave Jordan Data Standards Project Leader 1

Outline TransCelerate Overview CFAST Overview Therapeutic Area Standards Project CDISC SHARE Q & A 2

Charter Members of TransCelerate BioPharma Member Representatives John Leonard (Board Member) SVP Chief Scientific Officer Briggs Morrison (Board Member) EVP, Global Medicines Development Paul Stoffels (Board Member) Worldwide Chairman of the Pharma Group Martin Fitchet (Treasurer) SVP Projects, Clinical Platforms & Sciences Jan Lundberg (Board Member) EVP of Science and Technology Klaus Dugi (Board Member) Corporate SVP, Medicines Mikael Dolsten (Board Member) President of Worldwide R&D John Hubbard (Alternate Board Member) SVP Development Operations Brian Daniels (Board Member) SVP Global Development & Medical Affairs Corsee Sanders (Board Member) Global Head of Development Innov. & Clin Ops Patrick Vallance (Board Member) President, Pharmaceuticals R&D Lynn Marks (Alternate Board Member) SVP, Clinical Platforms & Sciences Elias Zerhouni (Board Member) President of Global R&D 3

New Members of TransCelerate BioPharma - 2013 Member Representatives Sef Kurstjens (Board Member) CMO & President Pharma Global Development Alfred Sandrock (Board Member) SVP, Head of Development Sciences& CMO Garry Neal (Board Member) Head of R&D Marco Taglietti (Board Member) President, Forest Research Institiute & CMO Annalisa Jenkins (Board Member) Head of Global Development & Medical Pablo Cagnoni (Board Member) EVP, Global Head of R&D 4

The intent is not to re-create, but rather partner with existing collaborations which closely align with project activities Engagement with the Larger Ecosystem Outside organizations, including regulatory, public, government and industry-based entities, are being engaged. Industry Initiatives Health Advocacy TransCelerate BioPharma Inc. Regulatory Bodies Research and CRO Community 5

TransCelerate Clinical Data Standards Project Opportunity Description Long Term Vision: Create common Clinical Data Standards (therapeutic area in addition to existing safety domains) and metadata standards for integrating clinical data from disparate sources as a foundation for end-to-end data flow Goals: Dedicate effort and investments to assist [partner with] CDISC, C-Path and FDA to complete CFAST Therapeutic Area [TA] data standards projects more rapidly Roll-out new TA data standards every few months as particular disease areas are completed Also drive adoption to realize benefits and enable interoperability across companies, foundations, health authorities Standards are the key foundation for achieving vision for the semantic interoperability described in recent FDA draft Guidance for providing regulatory submissions in electronic format (standardized study data) ADaM = Analysis Data Model CDASH = Clinical Data Acquisition Standards Harmonization SDTM = Study Data Tabulation Model 6

Coalition For Accelerating Standards & Therapies CFAST - an initiative to accelerate clinical research and medical product development by creating and maintaining data standards, tools and methods for conducting research in therapeutic areas that are important to public health Objective - Identify common standards for representing clinical data for studies of drug products in specific, prioritized therapeutic areas [TA] To be implemented using CDISC structures (CDASH, SDTM) Support integration of clinical data from disparate sources as a foundation for end-to-end data flow 7

Therapeutic Area Standards Governance Model CFAST Steering Committee CFAST Scientific Advisory Comm. CDISC Leadership FDA CDISC C-Path TransCelerate BioPharma CFAST Program Manager(s) TA Project Core Teams Project Manager Terminology Lead Clinical Lead BRIDG Modeler Data Standards Lead Data Analyst Statistics Consultant Technical Writer C CFAST Support: IT Admin Communications CDISC Foundational Standards Teams Community and Process 8

CFAST TA Data Standards Development 2013 Plan cfast20130313_planv1.pdf 9

Diabetes Project Organization CFAST Steering Committee Project Leader CDISC CTO Process Consultants Project Tracking & Reporting Technical Writer Scoping & Input Team Terminology Team Concept Creators Metadata Analysts TA Clinical Experts CDISC CT Team BRIDG Consultant Works with SDS and CDASH liaisons Statistics/Analysis Experts Questionnaire Team Review Communities (CDISC, NCI, Diabetes Medical Associations, NIH, FDA, etc..) 10

TA Standards Development Initiative Core principles: 1. Use an open and transparent process 2. Adopt or adapt existing standards [data elements and terminologies], where possible 3. Ensure engagement and input of clinical and medical professional societies, as well as government agencies 4. Utilize a well-defined data standards governance function 5. Scope projects to develop standards incrementally 11

Definition of Requirements Documenting efficacy data requirements for individual TAs Primary and secondary outcome measures Key exploratory endpoints (including new biomarkers) Covariates Collect preliminary requirements from identified sources Drug development guidances for the identified TAs Public clinical trial information sources Submission documents (CRFs, clinical study reports, agency reviews) CDISC standards (e.g. SDTM IG) 12

Therapeutic Area Standards: Baseline Content Mindmap/model of disease area clinical concepts Essential core data elements with definitions, data types (simple & ISO 21090), BRIDG and SDTM mappings SDTM domains and examples Minimum value sets (code lists) with definitions and c- codes User/Implementation Guide with permissions statement Standard CDASH CRFs with SDTM annotations, as appropriate Ideally, ADaM Analysis model examples Possibly study design models 13

Single, trusted, authoritative source for CDISC data standards Concepts, metadata, collections, relationships, value sets across the full spectrum of CDISC content Links research to healthcare concepts to support interoperability Aligned with NCI Semantic Systems BRIDG, ISO21090 b. Gov c workflows a. Change control c. Impact Analysis & Inheritance Protocol, CDASH SDTM, ADaM a b c SHARE Facilitates Data Exchange Access to data standards Source to target mapping & traceability Transformation logic Terminologies Adapted from Source by Sue Dubman, Sanofi-Aventis 1 4 14

Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has. Margaret Mead Questions? 15